Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etanercept biosimilar for oral ulcers in Behcet's disease
jRCTs061250074Recruiting
- Start
- Mar 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of etanercept in Behçet's disease (BD). Primary endpoint: Primary: AUC12 for oral ulcer burden. Started Mar 2026; status: recruiting.
02
Drugs
etanercept
03
Conditions
Behçet's disease (BD)
Beyond the preview
Go deeper on jRCTs061250074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061250074.